Global Healthcare Analyst

Tina Banerjee

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a> entered into a definitive agreement to acquire <a href="https://www.smartkarma.com/entities/shockwave-medical-inc" target="_blank" data-smartkarma-citation="entities:28730:1" rel="noopener">Shockwave Medical Inc (SWAV US)</a> for $335/share in cash or an enterprise value of $13.1B.</li>
<li>Offer price represents 4.7% premium over yesterday’s closing price or around 19% premium over the undisturbed price. The deal is expected to close by mid-2024.</li>
<li>With no product overlap and competition concern, the deal is expected to get regulatory approval. With reasonable deal valuation, shareholders approval is also expected.</li>
</ul>



Johnson &amp; Johnson (JNJ US) entered into a definitive agreement to acquire Shockwave Medical Inc (SWAV US) for $335/share in cash or an enterprise value of $13.1B.
Offer price represents 4.7% premium over yesterday’s closing price or around 19% premium over the undisturbed price. The deal is expected to close by mid-2024.
With no product overlap and competition concern, the deal is expected to get regulatory approval. With reasonable deal valuation, shareholders approval is also expected.


Shockwave Medical Inc (SWAV US): Johnson & Johnson (JNJ US)’s Acquisition Offer

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by surpassing set financial goals.</li><li>Throughout the year, total company operational sales grew by 15% and organic sales by 14%, exceeding the high-end guidance range of 8% to 10%.</li><li>Operational sales growth for the full year was registered at 13%, and organic sales grew by 12%.</li></ul>

Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by surpassing set financial goals.Throughout the year, total company operational sales grew by 15% and organic sales by 14%, exceeding the high-end guidance range of 8% to 10%.Operational sales growth for the full year was registered at 13%, and organic sales grew by 12%.

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? - Major Drivers

<ul>
<li>
<a href="https://www.smartkarma.com/entities/terumo-corp" target="_blank" data-smartkarma-citation="entities:6708:1" rel="noopener">Terumo Corp (4543 JP)</a> posted highest ever quarterly and YTD revenue and operating profit in Q3FY24. Double-digit growth in C&amp;V and TBCT businesses are the main revenue growth driver.</li>
<li>During 9MFY24, gross profit margin expanded 50bps YoY to 52%, while operating profit margin improved 40bps to 15.5%. Profitability improvement through price increases and cost reduction is on track.</li>
<li>Terumo has revised both FY24 revenue and profit upward to reflect continuing positive impacts from yen depreciation. The company is aiming for record high revenue and profit in FY24.</li>
</ul>



Terumo Corp (4543 JP) posted highest ever quarterly and YTD revenue and operating profit in Q3FY24. Double-digit growth in C&amp;V and TBCT businesses are the main revenue growth driver.
During 9MFY24, gross profit margin expanded 50bps YoY to 52%, while operating profit margin improved 40bps to 15.5%. Profitability improvement through price increases and cost reduction is on track.
Terumo has revised both FY24 revenue and profit upward to reflect continuing positive impacts from yen depreciation. The company is aiming for record high revenue and profit in FY24.


Terumo Corp (4543 JP): 3Q Result Beat Estimate; Currency Depreciation Led Full-Year Guidance Raise

<ul><li>Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product innovations, clinical evidence, and the dedication of global teams.</li><li>In Q3, the company achieved remarkable operational and organic growth, with total sales increasing by 11% operationally and 10% organically compared to Q3 '22.</li><li>The adjusted EPS for Q3 reached $0.50, a 15% increase over Q3 '22, exceeding the guidance range of $0.46 to $0.48.</li></ul>

Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product innovations, clinical evidence, and the dedication of global teams.In Q3, the company achieved remarkable operational and organic growth, with total sales increasing by 11% operationally and 10% organically compared to Q3 '22.The adjusted EPS for Q3 reached $0.50, a 15% increase over Q3 '22, exceeding the guidance range of $0.46 to $0.48.

Boston Scientific Corporation: Soaring High With New Products & The Acquisition Of Axonics! - Major Drivers

<ul><li>Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter.</li><li>In the second quarter, Boston Scientific witnessed a 12% growth in total company sales.</li><li>In the peripheral intervention segment, sales surged by 13% organically, while cardiology delivered impressive organic sales growth of 13%.</li></ul>

Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter.In the second quarter, Boston Scientific witnessed a 12% growth in total company sales.In the peripheral intervention segment, sales surged by 13% organically, while cardiology delivered impressive organic sales growth of 13%.

Boston Scientific Corporation: Delving Into Double-Digit Growth - Must-Know Info for Every Investor! - Major Drivers

United States

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Boston Scientific (BSX US)

Shockwave Medical Inc (SWAV US): Johnson & Johnson (JNJ US)’s Acquisition Offer

J&J to acquire Shockwave Medical for $335 per share. With no product overlap, the deal is expected to receive regulatory and shareholder...

Tina Banerjee

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? - Major Drivers

Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by...

Baptista Research

Terumo Corp (4543 JP): 3Q Result Beat Estimate; Currency Depreciation Led Full-Year Guidance Raise

Terumo reports record high quarterly revenue and operating profit in Q3FY24. Double-digit growth in C&V and blood center business and continued...

Tina Banerjee

Boston Scientific Corporation: Soaring High With New Products & The Acquisition Of Axonics! - Major Drivers

Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product...

Baptista Research

Boston Scientific Corporation: Delving Into Double-Digit Growth - Must-Know Info for Every Investor! - Major Drivers

Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter. In the second quarter, Boston Scientific...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Shockwave Medical Inc (SWAV US): Johnson & Johnson (JNJ US)’s Acquisition Offer

​J&J to acquire Shockwave Medical for $335 per share. With no product overlap, the deal is expected to receive regulatory and shareholder...

Tina Banerjee

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? - Major Drivers

Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by...

Baptista Research

Terumo Corp (4543 JP): 3Q Result Beat Estimate; Currency Depreciation Led Full-Year Guidance Raise

Terumo reports record high quarterly revenue and operating profit in Q3FY24. Double-digit growth in C&V and blood center business and continued...

Tina Banerjee

Boston Scientific Corporation: Soaring High With New Products & The Acquisition Of Axonics! - Major Drivers

Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product...

Baptista Research

Boston Scientific Corporation: Delving Into Double-Digit Growth - Must-Know Info for Every Investor! - Major Drivers

Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter. In the second quarter, Boston Scientific...

Baptista Research

J&J to acquire Shockwave Medical for $335 per share. With no product overlap, the deal is expected to receive regulatory and shareholder...